VolitionRx (NYSE:VNRX) Now Covered by StockNews.com

Investment analysts at StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a note issued to investors on Thursday. The brokerage set a “sell” rating on the stock.

Separately, Cantor Fitzgerald reiterated an “overweight” rating and set a $2.50 price objective on shares of VolitionRx in a research report on Wednesday, March 27th.

VolitionRx Price Performance

Shares of NYSE:VNRX opened at $0.60 on Thursday. The company has a market capitalization of $49.24 million, a PE ratio of -1.18 and a beta of 1.35. The business has a fifty day moving average price of $0.89 and a two-hundred day moving average price of $0.84. VolitionRx has a 1 year low of $0.55 and a 1 year high of $2.10.

VolitionRx (NYSE:VNRX) last posted its quarterly earnings results on Monday, March 25th. The company reported ($0.11) earnings per share for the quarter. The firm had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.50 million. Sell-side analysts anticipate that VolitionRx will post -0.4 earnings per share for the current year.

Institutional Trading of VolitionRx

An institutional investor recently bought a new position in VolitionRx stock. Silverberg Bernstein Capital Management LLC acquired a new position in VolitionRx Limited (NYSE:VNRX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 147,038 shares of the company’s stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned approximately 0.19% of VolitionRx as of its most recent SEC filing. Institutional investors and hedge funds own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.